Literature DB >> 17041605

Interface-disrupting amino acids establish specificity between T cell receptors and complexes of major histocompatibility complex and peptide.

Eric S Huseby1, Frances Crawford, Janice White, Philippa Marrack, John W Kappler.   

Abstract

T cell receptors (TCRs) bind complexes of cognate major histocompatibility complex (MHC) and peptide at relatively low affinities (1-200 microM). Nevertheless, TCR-MHC-peptide interactions are usually specific for the peptide and the allele encoding the MHC. Here we show that to escape thymocyte negative selection, TCRs must interact with many of the side chains of MHC-peptide complexes as 'hot spots' for TCR binding. Moreover, even when the 'parental' side chain did not contribute binding affinity, some MHC-peptide residues contributed to TCR specificity, as amino acid substitutions substantially reduced binding affinity. The presence of such 'interface-disruptive' side chains helps to explain how TCRs generate specificity at low-affinity interfaces and why TCRs often 'accommodate' a subset of amino acids at a given MHC-peptide position.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17041605     DOI: 10.1038/ni1401

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  62 in total

1.  Fast on-rates allow short dwell time ligands to activate T cells.

Authors:  Christopher C Govern; Michelle K Paczosa; Arup K Chakraborty; Eric S Huseby
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

2.  Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics.

Authors:  Oleg Y Borbulevych; Priscilla Do; Brian M Baker
Journal:  Mol Immunol       Date:  2010-07-08       Impact factor: 4.407

3.  Evolving concepts of specificity in immune reactions.

Authors:  Herman N Eisen; Arup K Chakraborty
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

Review 4.  T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.

Authors:  Melinda A Biernacki; Michelle Brault; Marie Bleakley
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

5.  High-affinity T cell receptor differentiates cognate peptide-MHC and altered peptide ligands with distinct kinetics and thermodynamics.

Authors:  Stephen P Persaud; David L Donermeyer; K Scott Weber; David M Kranz; Paul M Allen
Journal:  Mol Immunol       Date:  2010-03-23       Impact factor: 4.407

Review 6.  Polyspecificity of T cell and B cell receptor recognition.

Authors:  Kai W Wucherpfennig; Paul M Allen; Franco Celada; Irun R Cohen; Rob De Boer; K Christopher Garcia; Byron Goldstein; Ralph Greenspan; David Hafler; Philip Hodgkin; Erik S Huseby; David C Krakauer; David Nemazee; Alan S Perelson; Clemencia Pinilla; Roland K Strong; Eli E Sercarz
Journal:  Semin Immunol       Date:  2007-03-29       Impact factor: 11.130

7.  A new twist in TCR diversity revealed by a forbidden alphabeta TCR.

Authors:  Christine McBeth; Audrey Seamons; Juan C Pizarro; Sarel J Fleishman; David Baker; Tanja Kortemme; Joan M Goverman; Roland K Strong
Journal:  J Mol Biol       Date:  2007-11-17       Impact factor: 5.469

8.  Effect of CDR3 sequences and distal V gene residues in regulating TCR-MHC contacts and ligand specificity.

Authors:  Brian D Stadinski; Peter Trenh; Brian Duke; Priya G Huseby; Guoqi Li; Lawrence J Stern; Eric S Huseby
Journal:  J Immunol       Date:  2014-05-09       Impact factor: 5.422

9.  Shaping of the autoreactive regulatory T cell repertoire by thymic cortical positive selection.

Authors:  Julie Ribot; Geneviève Enault; Sylvie Pilipenko; Anne Huchenq; Maryline Calise; Denis Hudrisier; Paola Romagnoli; Joost P M van Meerwijk
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

Review 10.  The molecular basis of TCR germline bias for MHC is surprisingly simple.

Authors:  K Christopher Garcia; Jarrett J Adams; Dan Feng; Lauren K Ely
Journal:  Nat Immunol       Date:  2009-02       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.